American Heart Of Poland S.A.
- Address
- Ul. Parzeczewska 35, 95-100 Zgierz, Poland
Cardiovascular Diseases
At American Heart Of Poland S.A. in Zgierz, the main focus is on cardiovascular disease, especially acute coronary syndrome, myocardial infarction, and broader atherosclerotic cardiovascular disease. The trials are designed to test new treatment approaches, improve prevention, and reduce major heart-related events.
- Studies in acute coronary syndrome are evaluating ways to lower repeat procedures and improve recovery after coronary intervention.
- Research in heart failure is examining treatments aimed at reducing hospitalizations and cardiovascular death in symptomatic patients.
- Trials in myocardial infarction are exploring new anti-inflammatory strategies to reduce the risk of future major adverse cardiovascular events.
- Investigations in atherosclerotic cardiovascular disease are assessing whether lowering lipoprotein(a) can prevent heart attack and urgent revascularization.
Overall, this therapeutic area at American Heart Of Poland S.A. centers on better management of high-risk heart conditions through prevention-focused and event-reducing therapies.
Nutritional and Metabolic Diseases
The site also conducts research in nutritional and metabolic diseases, with a strong emphasis on type 2 diabetes and related metabolic control. These studies aim to improve blood sugar management and support cardiovascular health in people with overlapping risk factors.
- Clinical research in type 2 diabetes is comparing treatments intended to improve glucose control in patients already using standard background therapy.
- Metabolic studies are examining whether better control of HbA1c can be achieved with newer treatment options than with current comparators.
- Some trials connect diabetes care with heart protection, reflecting the close link between metabolic disease and cardiovascular risk.
This area highlights a practical goal: finding therapies that can manage metabolic disease more effectively while also supporting long-term cardiovascular outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in American Heart Of Poland S.A.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction. | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ziltivekimab | 2 | Unknown | 2023-05-09 | 2024-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.